LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

Home・Stock List・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Open

SectorHealthcare

67.4 -2.45

Buy Sell

Overview

Share price change

24h

Current

Min

Max

69.4

Key metrics
By Trading Economics
Income	292M 150M
Sales	-75M 377M
P/E Sector Avg	25.941 51.415
Profit margin	39.832
Employees	423
EBITDA	-97M 185M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+20.63% upside

Dividends
By Dow Jones
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	218M 7.9B
Previous open	69.85
Previous close	67.4

News Sentiment

By Acuity

14%

86%

22 / 346 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

60.49 / 70.14 Support & Resistance

Halozyme Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 May 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 May 2026, 22:27 UTC

Acquisitions, Mergers, Takeovers

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 May 2026, 22:12 UTC

Earnings

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 May 2026, 21:52 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs

15 May 2026, 00:00 UTC

Earnings

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 May 2026, 23:57 UTC

Acquisitions, Mergers, Takeovers

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 May 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 May 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 May 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 May 2026, 23:47 UTC

Earnings

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 May 2026, 23:47 UTC

Earnings

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 May 2026, 23:46 UTC

Earnings

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 May 2026, 23:46 UTC

Earnings

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 May 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 May 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 May 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 May 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 May 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 May 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 May 2026, 22:11 UTC

Acquisitions, Mergers, Takeovers

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 May 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 May 2026, 22:04 UTC

Earnings

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 May 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 May 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 May 2026, 22:00 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 May 2026, 21:55 UTC

Earnings

Nu Holdings 1Q EPS 18c >NU

14 May 2026, 21:55 UTC

Earnings

Nu Holdings 1Q Rev $4.97B >NU

Peer Comparison

Price change

Halozyme Therapeutics Inc Forecast

Price Target

By TipRanks

20.63% upside

12 Months Forecast

Average 84.48 USD 20.63%

High 96 USD

Low 66.41 USD

Based on 5 Wall Street analysts offering 12 month price targets forHalozyme Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Halozyme Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

60.49 / 70.14Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

22 / 346 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.